These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33676765)

  • 1. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
    Longhitano AP; Slavin MA; Harrison SJ; Teh BW
    Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
    Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
    Front Immunol; 2020; 11():762. PubMed ID: 32457743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies in haematological malignancies.
    Viardot A; Bargou R
    Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.
    Foster LH; Lum LG
    Expert Opin Biol Ther; 2019 Jul; 19(7):707-720. PubMed ID: 31081696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting T cells to hematological malignancies with bispecific antibodies.
    Velasquez MP; Bonifant CL; Gottschalk S
    Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bispecific antibodies in onco-hematology: Applications and perspectives].
    Barrière S; El-Ghazzi N; Garcia M; Guièze R
    Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
    Raje N; Anderson K; Einsele H; Efebera Y; Gay F; Hammond SP; Lesokhin AM; Lonial S; Ludwig H; Moreau P; Patel K; Ramasamy K; Mateos MV
    Blood Cancer J; 2023 Aug; 13(1):116. PubMed ID: 37528088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
    Salvaris R; Ong J; Gregory GP
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
    Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
    Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
    Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
    Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
    Frey NV; Porter DL
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):567-572. PubMed ID: 27913530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.
    Servais S; Lengline E; Porcher R; Carmagnat M; Peffault de Latour R; Robin M; Sicre de Fontebrune F; Clave E; Maki G; Granier C; Xhaard A; Dhedin N; Molina JM; Toubert A; Moins-Teisserenc H; Socie G
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):507-17. PubMed ID: 24406505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
    Algeri M; Del Bufalo F; Galaverna F; Locatelli F
    Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.